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Two minor proteins with molecular masses of 8.5 and 15.5 kDa were identified in feline calicivirus (FCV) virions. Direct
sequence analysis showed that the N-terminal sequence of the 8.5-kDa protein was identical to that of the predicted protein
encoded by open reading frame 3 (ORF3) of the FCV genome. The N-terminal sequence of the 15.5-kDa protein corresponded
to amino acids 961–980 of the FCV ORF1 polyprotein and mapped to the genomic location of the calicivirus VPg. Antisera
raised against recombinant ORF3 protein or the N-terminal 20 amino acids of the putative VPg reacted with the correspond-
ing proteins present in both a Western blot analysis of purified FCV virions and an immunofluorescence assay of FCV-infected
cells. A comparative analysis of radioactivity incorporated into virion proteins during in vivo labeling experiments indicated
that the ORF3 protein is likely present in one or two copies per virion. The mobility of the ORF3 protein present in virions was
similar to that of the ORF3 protein found in FCV-infected cells or expressed in bacteria. Direct N- and C-terminal sequence
analysis of the purified ORF3 protein obtained by expression in bacteria demonstrated the presence of intact, uncleaved
termini, suggesting that the observed difference between the calculated and the apparent masses in SDS–PAGE was not due
to proteolytic processing of the protein.
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aINTRODUCTION
Feline calicivirus (FCV) is a major agent of upper
respiratory tract disease in cats (Kahn and Hoover, 1976;
Gaskell, 1985). Symptoms of the virus-induced disease
include ulceration of the mucosa of the oral cavity and
the oropharyngeal area. The disease can also be asso-
ciated with rhinitis and conjunctivitis.
Replication of FCV occurs in the cytoplasm of cells. It
is accompanied by the synthesis of at least five nonstruc-
tural proteins and abundant synthesis of a capsid protein
precursor that undergoes rapid proteolytic cleavage dur-
ing the maturation process (Carter, 1989; Carter et al.,
1992b; Sosnovtsev et al., 1998). Cytopathic changes in
infected cells and formation of plaques can be observed
within 18–60 h postinfection. However, progeny virus can
be detected in the cell culture medium within 3 to 4 h
after infection (Fastier, 1957). The 35- to 40-nm FCV virion
is an icosahedral structure that contains a polyadenyl-
ated positive-sense single-stranded RNA genome of 7.7
kb that has three predicted open reading frames (ORFs)
(Carter et al., 1992a). ORF1 encodes a 195-kDa polypro-
tein precursor of the nonstructural proteins, ORF2 en-
codes a 73-kDa precursor of the capsid protein, and
ORF3 encodes a 106-amino-acid (aa) basic protein (cal-
culated mass 12 kDa) with unknown function.
The calicivirus capsid protein is likely involved in the
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193binding and entry of virus into cells. Antibodies that are
specific for the capsid protein can neutralize viral infec-
tion (Tohya et al., 1991; Guiver et al., 1992; Milton et al.,
992; Shin et al., 1993) and inhibit binding of recombinant
irus-like particles to cells (White et al., 1996). Little is
nown about the early stages of FCV infection and rep-
ication. It was suggested that FCV could enter cells by
ndocytosis (Kreutz and Seal, 1995). Following entry, the
iral RNA genome must interact with the cellular machin-
ry to initiate translation. It has been suggested that the
Pg protein may play an important role in this event
Sosnovtsev and Green, 1995; Herbert et al., 1997). The
Pg was shown to be covalently linked to the 59-end of
iral RNA molecules purified from cells infected with San
iguel sea lion virus (Schaffer et al., 1980), FCV (Herbert
t al., 1997), or primate calicivirus (Pan-1) (Dunham et al.,
998). The removal of the VPg by proteinase digestion
ed to a significant decrease in the efficiency of in vitro
ranslation of FCV RNA purified from infected cells as
ell as the loss of infectivity of viral genomic RNA (Bur-
oughs and Brown, 1978; Herbert et al., 1997; Dunham et
l., 1998). Evidence for the presence of the VPg in virions
as been reported in studies of vesicular exanthema of
wine virus (Burroughs and Brown, 1978) and rabbit
emorrhagic disease virus (RHDV) (Meyers et al., 1991).
The presence of a minor structural protein encoded by
he 39-end ORF of the RHDV and Norwalk virus RNA
enomes has recently been demonstrated (Wirblich et
l., 1996; Glass et al., 2000). The nature of the association
f this minor protein with the virion and its function are
nknown; however, it was suggested that this protein
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194 SOSNOVTSEV AND GREENcould be associated with the RNA molecule because of
its basic amino acid composition (Neill et al., 1991).
Characterization of the proteins present in calicivirus
irions is important because it could lead to a better
nderstanding of the initial stages of virus replication.
he goal of this study was to analyze FCV virions for the
resence of additional minor proteins encoded by the
irus genome. Specific antibodies were developed
gainst synthetic oligopeptides or several virus-specific
olypeptides from different regions of the genome ex-
ressed in bacterial cells and used to analyze concen-
rated, purified FCV particles. In addition, the proteins in
hese particles were characterized by direct sequence
nalysis. This approach allowed us to identify the pres-
nce of VPg and the basic protein encoded by ORF3 of
he genome in FCV virions.
RESULTS
pecificity of antisera to recombinant proteins and
dentification of the ORF3 and VPg proteins in purified
CV virions by Western blot analysis
To express proteins encoded by ORF3 and the 59-end
egion of ORF2 (aa 1–115), we subcloned the corre-
ponding cDNA fragments into pET-28b (Fig. 1A). The
esulting plasmids, pHisF3 and pLC, respectively, were
erified by nucleotide sequencing and transformed into
scherichia coli (BL21) cells. Bacterial cells harboring
hese plasmids were treated with isopropyl-b-D-thioga-
lactopyranoside (IPTG) to induce expression of recombi-
nant proteins. SDS–PAGE analysis of the induced bacte-
rial cells showed the presence of expression products
corresponding in size to the predicted full-length recom-
binant proteins encoded by these plasmids. Western blot
analysis of induced bacterial cell fractions using Ni-
nitrilotriacetic (Ni-NTA)-alkaline phosphatase conjugate
(Qiagen) demonstrated that the expressed His-tagged
proteins could be found in both soluble and insoluble
fractions of the cells (data not shown). However, the
majority of the expressed ORF3 and LC proteins accu-
mulated in the fraction of insoluble proteins (40% of the
fraction) (Fig. 1B, lanes 4 and 6, respectively). The pro-
teins of the insoluble fraction were solubilized in the
urea-containing buffer and subjected to the immobilized-
metal affinity chromatography (IMAC) purification proce-
dure using Ni-NTA agarose column (Qiagen). Most of the
contaminating bacterial proteins were removed by suc-
cessive washes of the column with the same urea-con-
taining buffer at pH 8.0 and 6.3. The recombinant pro-
teins were eluted with the same buffer at pH 5.3 and
were more than 90% pure (Fig. 1B, lanes 7 and 8).
Approximately 300 mg of the purified and dialyzed pro-
teins was inoculated into guinea pigs in a three-step
immunization procedure (100 mg each dose). Each anti-erum reacted with its corresponding protein antigen in
Western blot (Fig. 1B, lanes 10 and 12). In addition,ach antiserum recognized a protein expressed in FCV-
nfected Crandell-Rees feline kidney (CRFK) cells at 24 h
ostinfection, but did not react with uninfected cells in
ndirect immunofluorescence experiments (Fig. 1C).
These sera were employed to investigate whether the
RF3 and the capsid precursor leader proteins were
resent in FCV virions. Virus was grown in CRFK cells
nd purified in CsCl gradients. Electron microscopy anal-
sis of the final virus sample (with a density of 1.36 g/ml)
howed a uniform population of full particles (.95%)
data not shown). Samples of purified virions containing
pproximately 20 mg of protein were subjected to SDS–
PAGE separation, followed by transfer to a nitrocellulose
membrane and probing with the corresponding pre- and
postimmunization sera. Virions (approximately 0.4 mg)
that were probed with anti-FCV serum (aVIR) were in-
luded as a control for the presence of mature capsid
rotein (Fig. 2, lanes 1 and 2). Analysis of virions with the
erum raised against the leader sequence (aLC) of the
capsid precursor failed to detect either the 14-kDa
cleaved leader protein or the presence of the 73-kDa
uncleaved capsid precursor (Fig. 2, lanes 3 and 4). The
ORF3 protein-specific serum recognized a single band
corresponding to a protein with a mobility of approxi-
mately 8.5 kDa (Fig. 2, lane 5).
In parallel, the same amount of FCV virion protein was
analyzed by immunoblotting using antisera specific for
nonstructural proteins (including the putative helicase,
protease, and polymerase regions) encoded by ORF1 of
the virus genome (Sosnovtsev and Green, in prepara-
tion). With the exception of antiserum raised against an
N-terminal peptide of the 14-kDa putative VPg protein
described earlier as one of the products of autocatalytic
processing of the C-terminal part of ORF1 polyprotein
(Sosnovtseva et al., 1999), the results of this immunoblot
analysis were negative (data not shown). The anti-pep-
tide serum (aVPg) recognized a virion protein with an
approximate mass of 15.5 kDa in the immunoblot (Fig. 2,
lanes 7 and 8). This serum also recognized a 14-kDa
protein in immunoblot and immunoprecipitation analyses
of the FCV ORF1 cleavage products generated by in vitro
translation or by expression in bacteria. The specificity of
this recognition for the 14-kDa in vitro expressed protein
was demonstrated in a competitive binding assay, in
which increasing quantities of the VPg peptide were
incubated with in vitro radiolabeled products encoded by
pVPP (including the 14-kDa protein) and aVPg serum
Fig. 3A). Immunoprecipitation of the VPg protein was
artially inhibited beginning with addition of 100 ng of the
Pg peptide and completely inhibited with 10 mg of the
Pg peptide. In addition, the aVPg serum was found to
recognize the corresponding antigen in infected cells by
immunofluorescence assay (Fig. 1C).
The presence of the ORF3 and VPg proteins in other
FCV virions was confirmed by analysis of three addi-
tional FCV strains (KCD, CFI, and NADC) that were pro-
f195ORF3 AND VPg PROTEINS IN FELINE CALICIVIRUS VIRIONSFIG. 1. (A) Schematic representation of the FCV genome. Regions of ORF1, 2, and 3 proteins used to raise specific antisera in guinea pigs in this
study are depicted as black bars. Limits of the sequence are indicated by the position of the first and last amino acids using the numbering system
of the URB strain (GenBank Accession No. L40021). The genomic location of the clones used for expression of the recombinant proteins is shown
using solid lines. Gray lines indicate the presence of vector plasmid sequence fused to the viral sequence. (B) Analysis of expression of the ORF3
and capsid leader sequence (LC) proteins encoded in plasmids pHisF3 and pLC, respectively, in bacterial cells. Bacterial cells carrying the pLC
plasmid, the pHisF3 plasmid, or the pET-28b vector plasmid were induced with IPTG, and the soluble (solub) or insoluble (insol) bacterial products
were prepared as described under Materials and Methods. The bacterial products were subjected to SDS–PAGE and visualized with Coomassie blue
stain: lane 1, pET-28b, soluble fraction; lane 2, pET-28b, insoluble fraction; lane 3, pHisF3, soluble fraction; lane 4, pHisF3, insoluble fraction; lane 5,
pLC, soluble fraction; lane 6, pLC, insoluble fraction. The recombinant proteins HisF3 and LC were purified using Ni-NTA agarose (lanes 7, and 8,
respectively). The specificity of the sera raised against these proteins was assessed by Western blot analysis using the insoluble fraction of
IPTG-induced bacterial cells carrying each plasmid: pET-28b (lane 9) and pHisF3 (lane 10) proteins were reacted with anti-HisF3 protein serum
(aORF3), and pET-28b (lane 11) and pLC (lane 12) proteins were reacted with anti-LC protein serum (aLC). (C) Indirect immunofluorescence of
FCV-infected CRFK cells 24 h postinfection. Panels represent the infected cells that were incubated with pre- and postimmunization sera specific for
virions (aVIR), capsid precursor leader protein (aLC), ORF3 protein (aORF3), or the N-terminal oligopeptide derived from the VPg protein (aVPg),
ollowed by incubation with secondary antibodies conjugated with FITC.
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196 SOSNOVTSEV AND GREENvided by Dr. J. Neill (USDA, Ames, IA). The ORF3 and VPg
proteins were present in purified virions from these three
strains as determined by reactivity with the specific an-
tibodies in a Western blot (data not shown).
The specificity of the antibodies against the leader
sequence of the capsid precursor was examined further.
We observed immunoprecipitation of the full-length 73-
kDa capsid precursor protein derived from in vitro trans-
lation of the FCV ORF2 clone pfD20 (Fig. 3B, lane 1),
indicating that the antibodies could react with the un-
cleaved form of the leader sequence. In FCV-infected
cells, the predominant product of precipitation was a
protein of approximately 13–14 kDa that corresponded to
the expected mass of the cleaved leader sequence (Fig.
3B, lane 3).
Stoichiometric ratio of structural proteins
The copy number of ORF3 and VPg proteins in the
virion was investigated. Virions were radiolabeled with
[35S]methionine in vivo, purified in a CsCl gradient, and
nalyzed by SDS–PAGE. Preliminary analysis indicated
hat the efficient release of ORF3 protein from virions
ccurred after the sample was heated at 70°C for 10 min
n SDS–PAGE sample buffer with 2% mercaptoethanol.
he protein could be detected as a minor band with a
obility similar to that of the corresponding protein iden-
ified by immunoblot analysis of nonradiolabeled virions
Fig. 4A, lane 2). However, under these conditions, the
ntensity of the band corresponding to the VPg protein
as weak and could be seen only after prolonged expo-
ure of the film. Heating of the sample at 100°C for at
east 10 min led to an increase in the intensity of the VPg
and region that varied from experiment to experiment,
hile the observed amount of the ORF3 protein re-
FIG. 2. Western blot analysis of purified FCV virions. The virion
proteins were separated by SDS–PAGE in 10–20% Tris–glycine gel
(Novex), blotted to nitrocellulose, and probed with post- and pre-aVIR,
lanes 1 and 2; aLC, lanes 3 and 4; aORF3, lanes 5 and 6; and aVPg,
anes 7 and 8.ained relatively the same (Fig. 4A, lane 1). The ob-
erved variability in the intensity of the VPg band mightesult from differences in the efficiency of the boiling
rocedure and RNA degradation. In addition, heating of
he sample at 100°C led to the appearance of additional
ands and the comigration of some of these proteins
ith VPg may have led also to the observed differences
n the VPg band intensity from experiment to experiment.
fforts to increase the “purity” of the virions by repeated
entrifugation in CsCl gradients had no effect on the
bserved protein profiles at either temperature. Compar-
tive analysis of the radioactivity incorporated into the
apsid and ORF3 proteins was conducted using a Phos-
horImager (Molecular Dynamics) for virus samples that
ere heated at 70°C. The radiolabel signal in the capsid
rotein was an average of 586 times higher than the
ignal in the ORF3 protein (Fig. 4B). Given that virions of
alicivirus were found to consist of 180 molecules of
apsid protein (Prasad et al., 1994) and that the amino
cid sequences of the mature FCV capsid protein and
he ORF3 protein contain nine and two methionines,
espectively, the calculated copy number for the ORF3
rotein is equal to 1.38 per particle. Determination of the
Pg copy number was inconclusive. However, the ob-
FIG. 3. Immunoprecipitation analysis of aVPg and aLC sera. (A)
Immunoprecipitation of radiolabeled 14-kDa protein obtained in a cou-
pled TNT reaction from pVPP plasmid using aVPg serum. A 10-min
incubation at 65°C of TNT products derived from pVPP leads to a
nonspecific precipitation of most of the protein, while significant
amounts of 14-kDa protein remain soluble. Experiments in lanes 1–8 of
A were performed using this “soluble” form of radiolabeled 14-kDa
protein. Lane 1, the 14-kDa protein, without serum. Lane 2, the 14-kDa
protein incubated with preimmunization aVPg serum. The specificity of
binding of the aVPg serum to the 14-kDa protein was examined by
competition with increasing amounts of free VPg peptide. Lanes 3–8,
the 14-kDa protein incubated with postimmunization aVPg serum and
no peptide (lane 3) or increasing VPg peptide concentrations of 1 ng
(lane 4); 10 ng (lane 5); 100 ng (lane 6); 1 mg (lane 7); 10 mg (lane 8). (B)
The post- and pre-aLC serum was used to immunoprecipitate radiola-
beled proteins derived in an in vitro system from plasmid pfD20 (FCV
capsid precursor) (lanes 1 and 2, respectively) or present in lysates of
FCV-infected CRFK cells (lanes 3 and 4, respectively).
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197ORF3 AND VPg PROTEINS IN FELINE CALICIVIRUS VIRIONSserved intensities of the VPg and ORF3 protein bands in
Coomassie blue-stained gels were similar, suggesting
that the stoichiometric concentration of VPg would likely
not exceed that of the ORF3 protein.
FIG. 4. Analysis of in vivo radiolabeled FCV virions. (A) Temperature-
dependent “release” of VPg protein. The virions were heated at 100 or
70°C for 10 min in the gel-loading buffer prior to loading (lanes 1 and
2, respectively). (B) Incorporation of radioactivity into the capsid (CAP)
and ORF3 proteins of FCV virion (data from representative experiment).
Three wells were loaded with the same amount of virions. Amounts of
relative light units (RLU) corresponding to radioactivity incorporated
into the proteins were counted using a PhosphorImager (Molecular
Dynamics). Bars represent the mean value of three measurements.
FIG. 5. Visualization of FCV virion proteins used for direct sequence a
Lane 1, virion proteins were subjected to SDS–PAGE in 10–20% Tris–gly
of virion protein used to determine the N-terminal sequence of the mi
markers (Novex) corresponding to molecular masses of 98, 64, 50, 36,
IPTG-induced bacterial cells carrying the pF3 plasmid. Lanes 4–9, ORF
in vitro system from pF3 (lanes 4 and 5; post- and preimmunization se
espectively), and in FCV-infected cells (lanes 8 and 9; post- and preimmunizat
rotein detected by Coomassie blue staining.The presence of the ORF3 and VPg proteins in virions
was confirmed by immunoprecipitation analysis. Similar
to the immunoblot experiments, attempts to identify the
capsid leader sequence or proteins encoded by the virus
genome ORF1 (other than the VPg) failed (data not
shown).
Genomic mapping of the ORF3 and VPg proteins
Direct sequence analysis was performed on the two
virion-associated proteins in order to confirm their ami-
no-termini. The ORF3 and VPg proteins could be readily
detected when 20 mg of the FCV virions was analyzed by
DS–PAGE and stained with GelCode Blue Stain (Pierce)
ontaining colloidal Coomassie blue sensitive to nano-
ram amounts (8 ng per band) of protein (Fig. 5, lane 1).
hen gels were loaded with 160 mg of the FCV virions,
he ORF3 and VPg proteins were detectable after stain-
ng with conventional solutions of Coomassie blue R-250
nd their amounts were sufficient to conduct direct N-
erminal sequencing. The N-terminal sequence of the
irion ORF3 protein matched the beginning of the pre-
icted protein encoded by the ORF3 sequence (with
ome ambiguity in the Met position). The beginning of
he VPg protein was shown to be identical to the N-
erminus of a 14-kDa protein (corresponding to aa resi-
ue 961 of the FCV ORF1 polyprotein) described previ-
usly as a product of autocatalytic processing of the
-terminal part of the ORF1 polyprotein (Sosnovtsev et
l., 1998; Sosnovtseva et al., 1999). As previously re-
orted by Carter et al. (1992b), the N-terminus of the
and comparison of the mobilities of different forms of the ORF3 protein.
l (Novex) and visualized with GelCode Blue Stain (Pierce). The amount
ctural proteins was eight times higher (not shown). Lane 2, SeeBlue
and 6 kDa (from top to bottom of gel). Lane 3, insoluble fraction of the
noprecipitation analysis of the radiolabeled proteins synthesized in an
ectively), from pfD20 (lanes 6 and 7; post- and preimmunization sera,nalysis
cine ge
nor stru
30, 16,
3 immu
ra, respion sera, respectively). Lane 10, bacteria-expressed and purified ORF3
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198 SOSNOVTSEV AND GREENmature capsid protein began at the alanine residue at
position 125 of the predicted protein encoded by ORF2.
Comparison of the observed mobilities of the ORF3
and VPg proteins in virions with those expressed in
FCV-infected cells or from cDNA clones.
The calculated mass of the protein encoded by ORF3
of the FCV genome is 12.2 kDa. It was previously re-
ported that serum raised against a recombinant ORF3
protein recognized a smaller-appearing protein of ap-
proximately 8–9 kDa in FCV-infected CRFK cells (Herbert
et al., 1996; Tohya et al., 1999). In order to investigate the
reason for this apparent discrepancy in size, we engi-
neered plasmid pF3, containing the ORF3 sequence
downstream of a bacterial translation signal and under
control of the T7 RNA polymerase promoter. The recom-
binant ORF3 protein was analyzed in both an in vitro
system (TNT) and bacteria. As shown in Fig. 5, lane 3, the
mobility of the ORF3 protein expressed in bacteria was
apparently identical with that of the ORF3 protein in
virions and corresponded to a molecular mass of 8.5
kDa. Expression of pF3 in the TNT system resulted in a
protein with the same observed mobility (Fig. 5, lane 4).
We also detected synthesis of an ORF3 protein of iden-
tical mobility in products of in vitro translation of the
subgenomic template encoded by pfD20 (Fig. 5, lane 6).
The translation of the ORF3 protein from a bicistronic
subgenomic RNA template was consistent with previous
FCV studies (Herbert et al., 1996). The mobility of the
ORF3 protein found in virions, and synthesized in vitro,
and in bacteria corresponded to the mobility of the ORF3
protein produced in FCV-infected CRFK cells (Fig. 5,
lane 8).
A possible explanation for the apparent discrepancy
between the calculated mass and the observed mass
was that the ORF3 protein might be proteolytically pro-
cessed. To investigate whether the predicted 12.2-kDa
protein encoded by ORF3 might undergo an autocatalytic
processing event giving rise to a smaller 8.5-kDa prod-
uct, we analyzed the N- and C-terminal sequences of the
purified “authentic” ORF3 protein expressed in bacteria
from plasmid pF3 (Fig. 5, lane 10). Direct N-terminal
sequencing demonstrated that the first 20 amino acids of
the N-terminus of the protein matched the N-terminal
sequence of the predicted ORF3-encoded protein begin-
ning at the initiating methionine. Direct C-terminal se-
quencing showed that the last 5 amino acids of that
protein were identical to the C-terminal sequence of the
predicted ORF3-encoded protein.
The calculated molecular mass of the VPg protein is
12.6 kDa. However, the observed mobility of this protein
expressed in bacterial cells or in an in vitro system
(pVPP) corresponded to a molecular mass of approxi-
mately 14 kDa (Sosnovtseva et al., 1999). The observed
mobility of the VPg protein found in virions was approx-imately 15.5 kDa (Fig. 6, lanes 1, 2, and 6). To examine
which form of the VPg protein is present in infected cells,
we conducted immunoprecipitation analysis of radiola-
beled virus proteins from FCV-infected CRFK cell lysates
using aVPg serum. The antibodies immunoprecipitated a
rotein of the same mobility as the 14-kDa VPg protein
xpressed in bacteria, indicating that the predominant
orm of the VPg protein in infected cells is different from
he form of VPg (15.5 kDa) detected in mature virions.
everal faint bands of varying intensity in the range from
4 to 15.5 kDa were barely detectable among the immu-
oprecipitation products. Precursor proteins with molec-
lar masses of approximately 120, 90, 43, and 33 kDa
ere precipitated also from infected cells with aVPg
serum (Fig. 6, lanes 3 and 4). In some bacteria expres-
FIG. 6. Comparison of the VPg protein in virions with that derived by
cleavage of the ORF1 polyprotein in vitro or synthesized in FCV-infected
cells. Insoluble fraction of IPTG-induced bacterial cells carrying pVPP
plasmid (lane 1), FCV virions (lane 2), and VPg-related proteins immu-
noprecipitated from FCV-infected cells (lanes 3 and 5, postimmuniza-
tion serum; lane 4, preimmunization serum) as well as from radiola-
beled FCV virions (lane 6, postimmunization serum) were subjected to
SDS–PAGE in a 12.5% Tris–glycine gel. The proteins were stained with
GelCode Blue Stain (Pierce), dried, and exposed to film. The location of
the VPg protein in each lane is indicated with an arrow. The asterisk
marks the pVPP protein band corresponding to the protein found to be
part of FCV proteinase.sion experiments, we observed a minor 15- to 16-kDa
protein band in the proteolytic products derived from
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199ORF3 AND VPg PROTEINS IN FELINE CALICIVIRUS VIRIONSpVPP (Fig. 6, lane 1, indicated with an asterisk). However,
direct N-terminal sequencing showed that this protein
corresponded to the N-terminus of the FCV proteinase
(beginning with aa 1072).
DISCUSSION
Our finding that the ORF3 protein is present in FCV
virions confirms that it is a minor structural protein and
contradicts the suggestion that this protein may be non-
structural (Tohya et al., 1999). Difficulties associated with
the detection of this protein in virions might be explained
by its low copy number or the reactivity of the serum
raised against recombinant protein. According to the
comparative analysis of radioactivity incorporated into
virion proteins, the ORF3 protein is present in only one or
two copies per virion. The observed mobility of the virion
ORF3 protein was similar to that of the protein found in
infected cells and in bacterial or in vitro expression
systems. This mobility corresponded to a molecular
mass of about 8.5 kDa, which was consistent with data
reported previously (Herbert et al., 1996; Tohya et al.,
1999). Our present data suggest that the lower observed
molecular mass of the ORF3 protein is related to an
unusual mobility in SDS–PAGE. The probability of spe-
cific co- or posttranslational modification of the ORF3
protein is unlikely because the protein showed similar
mobilities after expression in several different systems. It
is also unlikely that this protein undergoes autocatalytic
cleavage because the mobility of the ORF3 protein ex-
pressed in bacteria was approximately 8.5 kDa and con-
tained intact N- and C-terminal sequences. Moreover,
direct N-terminal sequence analysis of the ORF3 protein
from the native virions was consistent with the absence
of proteolytic processing at the N-terminus.
All caliciviruses examined thus far possess a terminal
ORF analogous to FCV ORF3. The proteins encoded by
these terminal ORFs show considerable variation in pri-
mary amino acid sequence and calculated molecular
mass. However, they are all likely translated from a
bicistronic subgenomic RNA template coterminal with
the 39-end of the genome, and the predicted proteins
exhibit an overall basic amino acid composition. It was
proposed that the protein encoded by the terminal ORF is
involved in specific encapsidation of the viral genome
into particles through interactions with both capsid pro-
tein and the viral RNA (Neill et al., 1991; Wirblich et al.,
996). The available X-ray crystallography data show an
nternal localization of the acidic N-terminal domain of
he Norwalk virus capsid protein in virus-like particles
hat might serve as a structural basis for ORF3 protein–
apsid protein interactions (Prasad et al., 1999). Of inter-
st, the ORF3 protein and the genomic viral RNA are not
equired for self-assembly of the capsid protein into
irus-like particles (Laurent et al., 1994; Leite et al., 1996;
illiams et al., 1997). Further studies will be needed toddress the mechanisms by which capsid, ORF3 protein,
nd VPg-linked genomic RNA interact during packaging
nd assembly. The ORF3 protein may also play a regu-
atory function during virus replication. It is likely that the
ynthesis of the ORF3 protein from the subgenomic RNA
emplate is controlled at the translational level (Neill et
l., 1991; Herbert et al., 1996). Our preliminary data indi-
ate that the ORF3 protein is required for productive virus
eplication because a mutation that introduced a stop
odon in the beginning of ORF3 in an infectious FCV
DNA clone prevented recovery of viable virus (data not
hown).
The second minor protein found in FCV virions
apped to the region of ORF1 immediately upstream of
he sequence encoding the viral proteinase. This region
ad previously been mapped as encoding the VPg pro-
ein of the RHDV and Pan-1 caliciviruses (Wirblich et al.,
996; Dunham et al., 1998). Processing of this part of the
CV ORF1 polyprotein at two cleavage sites, E960–A961
and E1071–S1072, by the viral proteinase leads to the re-
lease of the VPg protein with an apparent molecular
mass of 14 kDa and a calculated mass of 12.7 kDa
(Sosnovtseva et al., 1999). The smallest major VPg-re-
lated protein immunoprecipitated from FCV-infected cells
had an apparent mass of 14 kDa in SDS–PAGE. However,
the VPg protein identified in FCV virions appeared
slightly larger with a mass of approximately 15.5 kDa.
The 15.5-kDa VPg band could be detected in polyacryl-
amide gels, after boiling or RNase T1 treatment of the
virion sample (data not shown). RNase T1 cleaves RNA
chains between the 39-phosphate group of a guanine
ribonucleotide and the 59-hydroxyl of the adjacent nucle-
otide, suggesting that a guanine ribonucleotide might
remain associated with the 15.5-kDa form of the VPg
protein after this treatment. The weak intensity of the
15.5-kDa VPg band in virion samples heated at 70°C
(compared to its stronger intensity after boiling) may
have also been the result of the association of RNA with
the VPg that retarded its migration in gels. The picorna-
virus VPg is thought to be involved in the initiation of viral
RNA replication and was shown to act as a primer for the
viral RNA polymerase (Nomoto et al., 1977; Paul et al.,
1998). Furthermore, purified poliovirus RNA polymerase
was able to uridylylate VPg protein (Paul et al., 1998). The
presence of two poliovirus VPg protein forms, free and
attached to dinucleotide, was demonstrated in an anal-
ysis of poliovirus-infected cells (Crawford and Baltimore,
1983). In similar experiments, we found that the free VPg
was the predominant form of this protein in FCV-infected
cells. However, a faint protein band with a mobility sim-
ilar to that of the virion VPg protein was also detected
among the proteins immunoprecipitated from FCV-in-
fected cells. Two additional protein bands with mobilities
intermediate between that of the free and virion forms of
the VPg were also observed in infected cells. The pres-
ence of these forms may reflect modifications that the
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200 SOSNOVTSEV AND GREENVPg protein undergoes during viral replication. Further
studies are in progress to establish the nature of the FCV
VPg modification and its possible involvement in RNA
replication.
The aVPg serum also precipitated other proteins with
higher molecular masses from FCV-infected cells. The
VPg-related proteins could be detected 2–3 h postinfec-
tion and the 120- and 90-kDa proteins comigrated with
proteins precipitated by sera raised against proteinase
and polymerase proteins (data not shown). It is possible
that these larger proteins represent precursors contain-
ing the VPg protein analogous to those found in picor-
navirus-infected cells, such as 3ABCD and 3BCD (Grub-
man et al., 1984; Palmenberg, 1990). The origin of the 43-
and 33-kDa proteins is not clear and the relationships of
these proteins to the FCV ORF1 polyprotein are under
investigation.
In agreement with Tohya et al. (1999), we did not detect
the presence of the capsid precursor leader protein in
FCV virions. This protein could be readily detected in
FCV-infected cells by immunoprecipitation or by immu-
nofluorescence staining using the aLC serum. It is likely
that removal of the leader sequence is a requirement for
maturation of the virions. When amino acid mutations
reducing cleavage efficiency were introduced into the
capsid precursor cleavage site in an infectious FCV
clone, we could not detect production of infectious virus
particles, although evidence for replication was found
(Sosnovtsev et al., 1998). Furthermore, the size of the
leader protein found in infected cells corresponded to
the expected size of the N-terminal cleavage product of
the FCV capsid precursor as reported also by Tohya et al.
(1999), suggesting that the leader protein accumulates in
infected cells without further proteolytic processing.
However, the function of this protein remains unknown.
We have demonstrated the presence of two minor
proteins, VPg and ORF3, in the virions of FCV, strain URB.
The identification of these proteins in FCV virions is
consistent with other caliciviruses examined thus far and
indicates that calicivirus virions contain at least three
proteins—the capsid, VPg, and the product of the termi-
nal ORF of the genome. Because these “structural” pro-
teins are apparently conserved in all caliciviruses, we
propose that the mature capsid protein be designated
VP1 (virion protein 1) and that the terminal ORF product
be designated VP2 (virion protein 2). By convention, the
protein linked to the virus RNA would remain VPg (virion
protein-genome linked). Because members of the genus
Vesivirus are unique in that the capsid protein is ex-
pressed as a precursor, we propose that the uncleaved
form be designated preVP1. The cleaved, mature capsid
protein would then be designated VP1 and the cleaved
leader protein of the capsid protein precursor would be
designated LC (leader of capsid).MATERIALS AND METHODS
Virus amplification, virus purification, and labeling of
virus-specific proteins
The FCV strain URB used in this study was amplified in
CRFK cells and maintained as described previously
(Sosnovtsev et al., 1998). The virus particles were puri-
fied by two consecutive rounds of centrifugation in CsCl
gradients (Neill and Mengeling, 1988). Aliquots of the
virus were subjected to an additional third centrifugation
in an isopycnic CsCl gradient. The virus samples were
dialyzed twice against a 10003 volume of phosphate-
uffered saline (PBS) before Western blot analysis.
To prepare the virus particles radiolabeled with
35S]methionine, twenty-two 150-cm2 flasks containing
0% confluent CRFK cell monolayers were infected with
CV at a multiplicity of infection of 0.1 and incubated for
h at 37°C. The cell monolayers in seven flasks were
ashed with methionine-free medium and incubated in
he same medium for 30 min. The cells were washed
gain, and [35S]methionine was added at a concentration
of 70 mCi/ml (.1000 Ci/mmol; Amersham). Following
ncubation for 24 h at 37°C, flasks (with [35S]methionine
and without) were subjected to three cycles of freeze–
thawing, the cell lysates were combined, and the virus
was purified as described above.
The concentration of protein in the virus samples was
measured using the Coomassie Plus Protein Assay Re-
agent (Pierce) and bovine serum albumin as control.
Radiolabeling of virus-specific proteins in FCV-in-
fected CRFK cells was carried out as described (Sos-
novtsev et al., 1998).
Construction of expression plasmids
To raise antisera specific to FCV proteins, selected
regions of the virus genome were PCR-amplified from
the full-length FCV cDNA clone pQ14 (Sosnovtsev and
Green, 1995) as template and cloned into bacterial ex-
pression vector pET-28b (Novagen). Oligonucleotides 59-
ATATATGGATCCGGAAATGAATTCAATTTTGGGCTTG-39
and 59-TTATATAGCGGCCGCTTATCAATTCTTAAAC-
AAATTCC-39 were employed to amplify by PCR the DNA
fragment corresponding to the ORF3 sequence of the
FCV genome. The sequence of the first oligonucleotide
contained 21 nucleotides (nt) corresponding to the be-
ginning of the ORF3 sequence (nt 7317 to 7337 of the FCV
genome) and included an initiation codon (boldface type)
and a BamHI site (underlined). The second oligonucleo-
tide corresponded to the sequence complementary to
the end of ORF3 (nt 7618 to 7637) and contained a
termination codon (boldface type) and a NotI site (under-
lined).
To analyze FCV virions for the presence of the protein
representing the 14.2-kDa leader sequence of the capsid
precursor protein, a corresponding DNA fragment was
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CCGATGTGCTCAACCTGC-39 and 59-TTTATATGCGGC-
CGCCTAATCCCATGCCTTAGCAAC-39. The sequence of
the first oligonucleotide contained 15 nt corresponding to
the beginning of ORF2 (nt 5314 to 5328) and included the
initiation codon (boldface type) and a BamHI site (under-
lined). The second oligonucleotide corresponded to the
sequence complementary to nt 5641 to 5658 of the FCV
genome and included an engineered termination codon
(boldface type) and a NotI site (underlined).
Purified PCR fragments from each region were treated
with BamHI and NotI and ligated into BamHI–NotI-linear-
ized pET-28b. The resulting plasmids contained either
the ORF3 sequence (pHisF3) or the leader sequence of
the capsid precursor protein (pLC) fused to the vector
sequence encoding an N-terminal His6-tag under control
f the T7 RNA polymerase promoter and placed down-
tream from the bacterial ribosome binding site (Fig. 1A).
To express the authentic ORF3 sequence, plasmid pF3
as constructed by digestion and removal of the 109-bp
coRI–NcoI fragment from the plasmid pHisF3, followed
y treatment with the Klenow fragment of DNA polymer-
se I, and recircularization of the plasmid. The plasmid
F3 directed synthesis of a protein with an N-terminal
equence identical to that of the ORF3 protein (Fig. 1A).
Plasmids pfD20 and pVPP1 (Fig. 1A) were constructed
reviously and contained the subgenomic RNA se-
uence starting at nt 5302 through the poly(A) tract and
he 39-end sequence of ORF1 from nt 2843 to 5303,
espectively (Sosnovtsev et al., 1998).
xpression and purification of the recombinant
roteins and production of specific antiserum
The recombinant proteins LC and HisF3 were ex-
ressed in E. coli BL21 (DE3) cells that were transformed
with the corresponding plasmids. The cells were grown
in the presence of carbenicillin (50 mg/ml) in LB medium
t 37°C. When the A 600 of the culture reached 0.6, ex-
pression was induced by the addition of IPTG at a con-
centration of 1 mM. As a control for expression experi-
ments, bacterial cells transformed with vector plasmid
pET-28b were induced also. After 5 h of additional incu-
bation, the cells were collected by low-speed centrifuga-
tion, and the cell pellets were suspended in a buffer
containing 300 mM NaCl, 50 mM Na2HPO4 (pH 8.0) in
/10 of the original culture volume. After freeze–thawing,
he bacteria were sonicated and subjected to centrifu-
ation at 12,000 g for 20 min. The soluble supernatant
as collected, and the insoluble pellet was resuspended
n the same buffer, sonicated, and collected again by
entrifugation. Recombinant proteins of the insoluble
raction were purified by IMAC using Ni-NTA agarose
Qiagen). Briefly, the proteins were solubilized in a buffer
ontaining 8 M urea, 10 mM Tris–Cl, 100 mM Na2HPO4
(pH 8.0), and after the solution was clarified by centrifu- igation, Ni-NTA agarose was added. Following a 1-h in-
cubation, the protein–resin slurry was loaded into dis-
posable 5-ml plastic columns (Qiagen), and resin-bound
His-tag-containing proteins were washed and then
eluted by changing the pH of the buffer. The eluted
proteins were twice dialyzed against 10003 volume of
PBS and were used for immunization of guinea pigs as
described previously (Sosnovtseva et al., 1999).
In this study, we used antiserum raised against recom-
binant proteins corresponding to different parts of the
FCV nonstructural polyprotein encoded by ORF1. Cloning
and expression of these proteins will be described sep-
arately (Sosnovtsev and Green, in preparation). In addi-
tion, antibodies were raised in rabbits against an oli-
gopeptide corresponding to the first 20 amino acids (aa
961–980 of the FCV ORF1 polyprotein) of the putative VPg
protein. The N-terminal amino acids of this protein were
selected for oligopeptide synthesis because they repre-
sent a cluster of hydrophilic amino acids that are con-
served among corresponding calicivirus sequences
(Dunham et al., 1998). The site for the proteolytic cleav-
age (E960–A961) releasing the N-terminus of the VPg pro-
ein was determined previously (Sosnovtseva et al.,
999).
The induction of the expression of the ORF3 protein
ncoded by plasmid pF3 and preparation of the insoluble
raction of bacterial cells were similar to the procedures
escribed above. However, the final pellet was sus-
ended in a buffer containing 1 M urea, 50 mM Na2HPO4
(pH 8.4) in 1/20 of the original culture volume. The insol-
uble proteins were pelleted by centrifugation at 12,000 g,
and the supernatant was collected. The procedure, con-
sisting of resuspending the protein pellet and collecting
the supernatant after the sample centrifugation, was re-
peated several times using the same phosphate buffer
(pH 8.4) containing urea at sequentially increasing con-
centrations (1 to 8 M). Samples of the supernatants were
analyzed by SDS–PAGE. Most of the ORF3 protein was
solubilized with the buffer containing 2 to 4 M urea (data
not shown). The protein solution containing 4 M urea
was then loaded onto a Sepharose-Q column (Pharma-
cia, 15 ml of bed volume per 50 ml of the sample)
preequilibrated with the same phosphate buffer (pH 8.4)
containing 4 M urea. After the sample was loaded, the
column was washed with 50 ml of the sample buffer and
eluted with a pH gradient (8.4–5.4) in the same buffer.
The column fractions were collected and analyzed by
SDS–PAGE. The flowthrough fraction containing 95%
pure ORF3 protein was selected for further analysis.
In vitro coupled transcription and translation
experiments, immunoprecipitation, and Western blot
analysisOne to 5 mg of plasmid DNA was used as the template
n a coupled transcription and translation reaction (TNT
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radiolabeling of the synthesized protein, [35S]methionine
(.1000 Ci/mmol, Amersham) was used at a concentra-
tion of 1.5 mCi/ml.
The immunoprecipitation of FCV proteins synthesized
in the TNT system and the immunoprecipitation of viral
proteins from infected cell lysates and Western blot anal-
yses were performed as described previously (Sosnovt-
sev et al., 1998). The immunoprecipitation of viral pro-
teins from radiolabeled virus particles was conducted
under conditions similar to those for cell lysates. Briefly,
purified virus particles were disrupted in the presence of
0.5% SDS for 15 min at 37°C. The samples were then
diluted with PBS to adjust the concentration of SDS to
0.1% before incubation with antisera.
Indirect immunofluorescence
Guinea pig hyperimmune sera raised against the URB
strain virions or the recombinant proteins, as well as
rabbit serum raised against the VPg oligopeptide, were
diluted 1:100 in PBS containing 1% fetal bovine serum
and incubated with the methanol-fixed cell monolayers
overnight at 4°C. Following three washes with PBS, the
binding of primary antibodies to antigen was detected
with fluorescein isothiocyanate (FITC)-conjugated goat
anti-guinea or anti-rabbit IgG antibodies (Kirkegaard and
Perry Laboratories).
Protein sequencing
For direct N-terminal sequence analysis, proteins
were separated by SDS–PAGE with a tricine running
buffer (Novex), transferred to a ProBlott membrane (Ap-
plied Biosystems), and visualized by staining with 0.1%
Coomassie blue R-250 in 40% methanol and 1% acetic
acid for 1 min, followed by destaining in 50% methanol.
The band of interest was excised and subjected to se-
quence analysis with a Model 477A protein sequencer
coupled to a Model 120A PTH Analyzer (Applied Biosys-
tems) according to the manufacturer’s program NOR-
MAL-1.
To determine the C-terminal sequence of the recom-
binant ORF3 protein, 200 mg of chromatographically pu-
ified protein (see above) was desalted and concentrated
sing a PE/Applied Biosystems ProSorb sample prepa-
ation cartridge. Chemical sequencing was performed on
he Procise C protein sequencer (PE/Applied Biosys-
ems) and the data were collected and analyzed using
he PE/Applied Biosystems Model 610 Sequencing Soft-
are.
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